戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 he management of malignant and non-malignant refractory ascites.
2 .024) as predictors for ELF in patients with refractory ascites.
3 ild-Pugh class C cirrhosis, hyponatremia, or refractory ascites.
4 ment during follow-up evaluation, mainly for refractory ascites.
5 tic portosystemic shunt in the management of refractory ascites.
6 repeated large volume paracentesis (LVP) for refractory ascites.
7 may improve quality of life in patients with refractory ascites.
8 from the early ascitic stage to the stage of refractory ascites.
9 n of variceal rebleeding or for treatment of refractory ascites.
10 n of variceal rebleeding or for treatment of refractory ascites.
11  variceal rebleeding and 58 for treatment of refractory ascites.
12 urvival times of patients with cirrhosis and refractory ascites.
13 ssure and have been used in the treatment of refractory ascites.
14 afe and efficient to reduce and / or resolve refractory ascites.
15 in patients with liver cirrhosis can lead to refractory ascites.
16 ring management strategies for patients with refractory ascites.
17 d paracentesis in patients with recurrent or refractory ascites.
18 urvival times of patients with cirrhosis and refractory ascites.
19                                              Refractory ascites 24 (30%), hepatic encephalopathy 16 (
20    The most frequent indication for TIPS was refractory ascites (50 of 54; 93%).
21 e mortality in the subgroup of patients with refractory ascites (588 patients, adjusted hazard ratio
22 he model for end-stage liver disease (MELD), refractory ascites, a known predictor of mortality in ci
23 he North American Study for the Treatment of Refractory Ascites, a multicenter trial of 109 patients
24 ntagonist) was investigated for treatment of refractory ascites and appeared to be effective, but thi
25  sequelae of end-stage liver disease such as refractory ascites and esophageal varices for patients a
26 F occurred in 16 of 95 (16.8%) patients with refractory ascites and in four of 121 (3.3%) patients wi
27 eviews the available therapeutic options for refractory ascites and incorporates available data and c
28 ves survival in patients with cirrhosis with refractory ascites and portal hypertensive bleeding.
29    BEST PRACTICE ADVICE 4: All patients with refractory ascites and/or hepatic hydrothorax should be
30                      BEST PRACTICE ADVICE 5: Refractory ascites and/or hydrothorax should be managed
31 PS placement for variceal hemorrhage, 49 for refractory ascites, and 24 for hepatic hydrothorax (tota
32  ratios were 4.6 and 4.3 in the patient with refractory ascites at the two post-TIPS time points, res
33  seven patients with portal hypertension and refractory ascites before and 2 and 12 weeks after TIPS
34 n of a peritoneal drainage in a patient with refractory ascites due to liver cirrhosis.
35 of 12 or less who undergo TIPS placement for refractory ascites (especially in patients with MELD of
36                                     Large or refractory ascites frequently necessitates paracentesis.
37 nderwent TIPS creation for the management of refractory ascites had a significantly lower survival ra
38 ACTICE ADVICE 7: Well-selected patients with refractory ascites, hepatic hydrothorax, volume overload
39    Patients with TIPS indications other than refractory ascites/hepatic hydrothorax, vascular liver d
40                                              Refractory ascites is a costly and debilitating conditio
41                                              Refractory ascites is managed by repeated large volume p
42 -vis total paracentesis in the management of refractory ascites is unclear.
43 ly after TIPS, compared to the patients with refractory ascites (median reduction 65% vs. 55% of pre-
44 ere recurrent variceal bleeding (n = 25) and refractory ascites (n = 16).
45 of recurrent variceal hemorrhage (n = 40) or refractory ascites (n = 20) were studied.
46 temic shunt is indicated when control of the refractory ascites or hepatic hydrothorax is required.
47 l centers with de novo TIPS implantation for refractory ascites or secondary prophylaxis of variceal
48 ective beta-blockers (NSBB) in patients with refractory ascites or spontaneous bacterial peritonitis
49 c portosystemic shunting, such as those with refractory ascites or variceal bleeding.
50 ic shunt (TIPS) is used in the management of refractory ascites (RA) and variceal bleeds.
51   Patients with cirrhosis receiving TIPS for refractory ascites (RA) or for the secondary prophylaxis
52  unclear, and individuals with cirrhosis and refractory ascites (RA) treated with devices like Alfapu
53 utive series of patients with cirrhosis with refractory ascites (RA).
54 d death (LRD) associated with RH compared to refractory ascites (RA).
55                 In conclusion, patients with refractory ascites randomized to TIPS or repeated LVP ha
56      In a controversial study, patients with refractory ascites taking propranolol were found to have
57                                Patients with refractory ascites taking propranolol were found to have
58 ices, gastroesophageal variceal bleeding and refractory ascites than sub-acute group (P < 0.001).
59 S) is indicated for therapy of recurrent and refractory ascites, there is no evidence-based recommend
60                          In 50 patients with refractory ascites, TIPS creation was performed.
61 ial was performed in which 109 subjects with refractory ascites were randomized to either medical the
62                           Treating medically refractory ascites with TIPS risks early shunt-related m
63 nts for whom an indication for TIPS had been refractory ascites, with a history of OHE or of renal fa